兰索拉唑联合瑞巴派特治疗慢性非萎缩性胃炎患者的临床观察  

Clinical Observation of Lansoprazole Combined with Rebamipide on Patients with Chronic Non-atrophic Gastritis

作　　者：张文瑜[1] 杨元生[1] 曹海霞[1] 容海鹰[1] 

机构地区：[1]广东药学院附属第二医院/新海医院消化内科,广东广州510310

出　　处：《中国医药指南》2013年第29期312-313,共2页Guide of China Medicine

摘　　要：目的观察兰索拉唑联合瑞巴派特治疗慢性非萎缩性胃炎的临床疗效。方法 86例胃镜和取病理证实的慢性非萎缩性胃炎患者,随机分为甲组和乙组,分别治疗4周和8周,满疗程后观察临床症状、炎性因子、复查胃镜和病理变化。结果治疗后两组患者的临床症状、血生化指标及胃镜和病理结果均较治疗前明显改善,乙组疗效更显著,总有效率分别为88.37%和97.67%(Z=-2.44,P=0.015)。结论兰索拉唑联合瑞巴派特治疗慢性非萎缩性胃炎临床疗效确切,8周疗程效果更理想。Objective To observe the clinical effect of lansoprazole combined with rebamipide on the treatment of chronic non-atrophic gastritis（CNAG）. Methods Eighty six patients with CNAG were collected and divided into group A and group B, all patients were received lansoprazole and rebamipide therapy, group A for 4 weeks, B group for 8 weeks. The clinical symptoms, inflammatory factor, gastroscopy and pathological changes were observed after the treatment. Results The clinical symptoms, serum inflammatory factor contents, gastroscopy and pathological results of patients were improved in two groups after treatment, the total effective rates were 88.37% and 97.67% （Z=-2.44,P=0.015） in group A and group B respectively, the better outcome occurred in group B. Conclusion The therapy of lansoprazole associated with rebarnipide had a good efficacy on CNAG, the long course of treatment has a better effect.

关 键 词：慢性非萎缩性胃炎 兰索拉唑 活检 C反应蛋白 

分 类 号：R573.3[医药卫生—消化系统]